A phase II trial of carboplatin and ABI-007 in patients with unresectable stage IV melanoma, N057E

被引：0
|
作者：
Kottschade, L. A.
Suman, V. J.
Amatruda, T., III
McWilliams, R. R.
Dakhil, S. R.
Nikcevich, D. A.
Morton, R. F.
Fitch, T. R.
Jaslowski, A. J.
Markovic, S. N.
机构：
[1] Mayo Clin, Rochester, MN USA
[2] Metro Minnesota CCOP, St Louis Pk, MN USA
[3] Wichita Community Clin Oncol, Wichita, KS USA
[4] Duluth CCOP, Duluth, MN USA
[5] Iowa Oncol Res Assoc CCOP, Des Moines, IA USA
[6] Mayo Clin Scottsdale, Scottsdale, AZ USA
[7] St Vincent Reg Canc Ctr CCOP, Green Bay, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.9044
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9044
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II Trial of Nab-Paclitaxel (ABI-007) and Carboplatin in Patients With Unresectable Stage IV Melanoma A North Central Cancer Treatment Group Study, N057E
    Kottschade, Lisa A.
    Suman, Vera J.
    Amatruda, Thomas, III
    McWilliams, Robert R.
    Mattar, Bassam I.
    Nikcevich, Daniel A.
    Behrens, Robert
    Fitch, Tom R.
    Jaslowski, Anthony J.
    Markovic, Svetomir N.
    CANCER, 2011, 117 (08) : 1704 - 1710
  • [2] A phase II trial of carboplatin (C) and nab-paclitaxel (ABI-007-nab-P) in patients with unresectable stage IV melanoma: Final data from N057E
    Markovic, S. N.
    Suman, V. J.
    Kottschade, L. A.
    Amatruda, T.
    McWilliams, R. R.
    Dakhil, S. R.
    Nikcevich, D. A.
    Morton, R. F.
    Fitch, T. R.
    Jaslowski, A. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] A phase II trial of neoadjuvant ABI-007, carboplatin, and gemcitabine (ACG) in patients with locally advanced carcinoma of the bladde
    Smith, D. C.
    Grivas, P.
    Daignault, S.
    Hafez, K.
    Wood, D. P.
    Lee, C. T.
    Montie, J. E.
    Weizer, A. Z.
    Montgomery, J.
    Hussain, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [4] Phase II trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma
    Perez, D. G.
    Suman, V.
    Amatruda, T.
    Gornet, M.
    Morton, R.
    Jilani, S.
    Constantinou, C.
    Egner, J.
    Markovic, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Open-label, multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma.
    Hersh, EM
    O'Day, S
    Gonzalez, R
    Samlowski, WE
    Gordon, MS
    Hawkins, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 724S - 724S
  • [6] Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
    Stinchcombe, Thomas E.
    Socinski, Mark A.
    Walko, Christine M.
    O'Neil, Bert H.
    Collichio, Frances A.
    Ivanova, Anastasia
    Mu, Hua
    Hawkins, Michael J.
    Goldberg, Richard M.
    Lindley, Celeste
    Dees, E. Claire
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 60 (05) : 759 - 766
  • [7] Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors
    Thomas E. Stinchcombe
    Mark A. Socinski
    Christine M. Walko
    Bert H. O’Neil
    Frances A. Collichio
    Anastasia Ivanova
    Hua Mu
    Michael J. Hawkins
    Richard M. Goldberg
    Celeste Lindley
    E. Claire Dees
    Cancer Chemotherapy and Pharmacology, 2007, 60 : 759 - 766
  • [8] Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma
    Jamal, Rahima
    Lapointe, Rejean
    Cocolakis, Eftihia
    Thebault, Pamela
    Kazemi, Shirin
    Friedmann, Jennifer E.
    Dionne, Jeanne
    Cailhier, Jean-Francois
    Belanger, Karl
    Ayoub, Jean-Pierre
    Le, Huy
    Lambert, Caroline
    El-Hajjar, Jida
    van Kempen, Leon C.
    Spatz, Alan
    Miller, Wilson H., Jr.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [9] Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer
    Ibrahim, NK
    Samuels, B
    Page, R
    Doval, D
    Patel, KM
    Rao, SC
    Nair, MK
    Bhar, P
    Desai, N
    Hortobagyi, GN
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) : 6019 - 6026
  • [10] Tumor SPARC microenvironment signature (SMS) and plasma levels in a phase II trail of unresectable stage IV melanoma treated with nab-paclitaxel and carboplatin: A translational study of NCCTG trail N057E.
    Markovic, S.
    Suman, V.
    Trieu, V. N.
    Liu, X.
    Yeh, W.
    Hwang, L.
    Treece, T.
    Motamed, K.
    Pramanik, P.
    Desai, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345